Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction.
Ki20227 (0.1-1000 nM; 72 hours) with 100 and 1,000 nM almost suppresses M-NFS-60 cell growth and HUVEC cell growth, respectively.
Ki20227 (0.1-1000 nM; 1 hour) suppresses M-CSF-dependent c-Fms phosphorylation in a dose-dependent manner.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay
Cell Line:
M-NFS-60 cells, HUVEC cells, human A375 melanoma cells
Concentration:
0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM
Incubation Time:
72 hours
Result:
100 and 1,000 nM almost suppressed M-NFS-60 cell growth and HUVEC cell growth, respectively.
Cell Viability Assay
Cell Line:
RAW264.7 cell lysate
Concentration:
0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM
Incubation Time:
1 hour
Result:
Suppressed M-CSF-dependent c-Fms phosphorylation in a dose-dependent manner.
体内研究(In Vivo)
Ki20227 (orally;10-50 mg/kg/d for 20 days) of 50 mg/kg/d of Ki20227 for 20 days markedly decreases the osteolytic lesion areas.
ki20227 during global ischemia led to a significant deficit in microglial density in the CNS in mice, and CSF1R-inhibition led to a significant reduction in the neuronal density of mice.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
4-week-old male F344/NJcl-rnu rats
Dosage:
10, 20, and 50 mg/kg
Administration:
Orally; once per day for 20 days
Result:
Oral administration of 50 mg/kg/d markedly decreased the osteolytic lesion areas.